ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 08/09/23

2023-08-09 12:12:37 ET Zentalis Pharmaceuticals press release ( NASDAQ: ZNTL ): Q2 GAAP EPS of -$1.85. Cash and Marketable Securities Position: As of June 30, 2023, Zentalis had cash, cash equivalents and marketable securities of $553.0 million. For further details s...

Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing Identified azenosertib monotherapy RP2D, which more than doubles exposure levels, maintains safety and improves tolerability wit...

NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, tod...

2023-06-21 10:07:44 ET Gainers: Ocean Biomedical ( OCEA ) +43% . PetVivo Holdings ( PETV ) +23% . Patterson Companies ( PDCO ) +14% . Zentalis Pharmaceuticals ( ZNTL ) +5% . RenovoRx ( RNXT ) +4% . Losers: uniQure ( ...

2023-06-17 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...

2023-06-15 10:06:53 ET Gainers: Aldeyra Therapeutics ( ALDX ) +11% . Bioventus ( BVS ) +11% . IO Biotech ( IOBT ) +11% . Verastem ( VSTM ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Losers: Mersana Therapeutics ( MRSN...

2023-06-15 06:05:27 ET Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) prices a common stock offering of 11.03M at $22.66 per share, for total gross proceeds of ~$250M. The offering is expected to close on June 20, 2023. Net proceeds from the offering will be used to f...

2023-06-07 07:00:00 ET Summary High-yield dividend stocks are appealing, but they carry high amounts of risk. I demonstrate multiple examples. We present our new strategy to achieve high yields and 76 trades to snipe at market open. Written by Sam Kovacs Intr...

ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no tre...

2023-06-02 14:34:00 ET Shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL) were down 13.5% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence . The healthcare company closed last week at $30.05 then fell as low as $25.17 on Th...